Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

An Orphan CpG Island Drives Expression of a let-7 miRNA Precursor with an Important Role in Mouse Development.

Koerner MV, Chhatbar K, Webb S, Cholewa-Waclaw J, Selfridge J, De Sousa D, Skarnes B, Rosen B, Thomas M, Bottomley J, Ramires-Solis R, Lelliott C, Adams DJ, Bird A.

Epigenomes. 2019 Mar;3(1):7. doi: 10.3390/epigenomes3010007. Epub 2019 Mar 13.

2.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.

Clin Cancer Res. 2019 Jul 15;25(14):4375-4387. doi: 10.1158/1078-0432.CCR-18-4144. Epub 2019 Apr 11.

PMID:
30975663
3.

Toxicity of overexpressed MeCP2 is independent of HDAC3 activity.

Koerner MV, FitzPatrick L, Selfridge J, Guy J, De Sousa D, Tillotson R, Kerr A, Sun Z, Lazar MA, Lyst MJ, Bird A.

Genes Dev. 2018 Dec 1;32(23-24):1514-1524. doi: 10.1101/gad.320325.118. Epub 2018 Nov 21.

4.

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.

Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H.

Mol Cancer Ther. 2018 Dec;17(12):2551-2563. doi: 10.1158/1535-7163.MCT-18-0177. Epub 2018 Sep 14.

5.

Affinity for DNA Contributes to NLS Independent Nuclear Localization of MeCP2.

Lyst MJ, Ekiert R, Guy J, Selfridge J, Koerner MV, Merusi C, De Sousa D, Bird A.

Cell Rep. 2018 Aug 28;24(9):2213-2220. doi: 10.1016/j.celrep.2018.07.099.

6.

Genotype-targeted local therapy of glioma.

Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT Jr, Barker FG 2nd, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8388-E8394. doi: 10.1073/pnas.1805751115. Epub 2018 Aug 6.

7.

A mutation-led search for novel functional domains in MeCP2.

Guy J, Alexander-Howden B, FitzPatrick L, DeSousa D, Koerner MV, Selfridge J, Bird A.

Hum Mol Genet. 2018 Jul 15;27(14):2531-2545. doi: 10.1093/hmg/ddy159.

8.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.

Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP.

Oncotarget. 2017 Nov 24;8(65):109228-109237. doi: 10.18632/oncotarget.22650. eCollection 2017 Dec 12.

9.

Radically truncated MeCP2 rescues Rett syndrome-like neurological defects.

Tillotson R, Selfridge J, Koerner MV, Gadalla KKE, Guy J, De Sousa D, Hector RD, Cobb SR, Bird A.

Nature. 2017 Oct 19;550(7676):398-401. doi: 10.1038/nature24058. Epub 2017 Oct 11.

10.

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP.

Cancer Res. 2017 Aug 1;77(15):4102-4115. doi: 10.1158/0008-5472.CAN-16-2263. Epub 2017 Jun 16.

11.

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP.

Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.

12.

The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome.

Brown K, Selfridge J, Lagger S, Connelly J, De Sousa D, Kerr A, Webb S, Guy J, Merusi C, Koerner MV, Bird A.

Hum Mol Genet. 2016 Feb 1;25(3):558-70. doi: 10.1093/hmg/ddv496. Epub 2015 Dec 8.

13.

Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing.

Latos PA, Pauler FM, Koerner MV, ┼×energin HB, Hudson QJ, Stocsits RR, Allhoff W, Stricker SH, Klement RM, Warczok KE, Aumayr K, Pasierbek P, Barlow DP.

Science. 2012 Dec 14;338(6113):1469-72. doi: 10.1126/science.1228110.

14.

A downstream CpG island controls transcript initiation and elongation and the methylation state of the imprinted Airn macro ncRNA promoter.

Koerner MV, Pauler FM, Hudson QJ, Santoro F, Sawicka A, Guenzl PM, Stricker SH, Schichl YM, Latos PA, Klement RM, Warczok KE, Wojciechowski J, Seiser C, Kralovics R, Barlow DP.

PLoS Genet. 2012;8(3):e1002540. doi: 10.1371/journal.pgen.1002540. Epub 2012 Mar 1.

15.

Genomic imprinting-an epigenetic gene-regulatory model.

Koerner MV, Barlow DP.

Curr Opin Genet Dev. 2010 Apr;20(2):164-70. doi: 10.1016/j.gde.2010.01.009. Epub 2010 Feb 12. Review.

16.

The function of non-coding RNAs in genomic imprinting.

Koerner MV, Pauler FM, Huang R, Barlow DP.

Development. 2009 Jun;136(11):1771-83. doi: 10.1242/dev.030403. Review.

17.

An in vitro ES cell imprinting model shows that imprinted expression of the Igf2r gene arises from an allele-specific expression bias.

Latos PA, Stricker SH, Steenpass L, Pauler FM, Huang R, Senergin BH, Regha K, Koerner MV, Warczok KE, Unger C, Barlow DP.

Development. 2009 Feb;136(3):437-48. doi: 10.1242/dev.032060.

18.

H3K27me3 forms BLOCs over silent genes and intergenic regions and specifies a histone banding pattern on a mouse autosomal chromosome.

Pauler FM, Sloane MA, Huang R, Regha K, Koerner MV, Tamir I, Sommer A, Aszodi A, Jenuwein T, Barlow DP.

Genome Res. 2009 Feb;19(2):221-33. doi: 10.1101/gr.080861.108. Epub 2008 Dec 1.

19.

Silencing and transcriptional properties of the imprinted Airn ncRNA are independent of the endogenous promoter.

Stricker SH, Steenpass L, Pauler FM, Santoro F, Latos PA, Huang R, Koerner MV, Sloane MA, Warczok KE, Barlow DP.

EMBO J. 2008 Dec 3;27(23):3116-28. doi: 10.1038/emboj.2008.239. Epub 2008 Nov 13.

20.

Silencing by imprinted noncoding RNAs: is transcription the answer?

Pauler FM, Koerner MV, Barlow DP.

Trends Genet. 2007 Jun;23(6):284-92. Epub 2007 Apr 18. Review.

Supplemental Content

Loading ...
Support Center